{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:05:42Z","timestamp":1760299542415},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,25]],"date-time":"2017-02-25T00:00:00Z","timestamp":1487980800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00277-017-2948-3","type":"journal-article","created":{"date-parts":[[2017,2,25]],"date-time":"2017-02-25T09:18:19Z","timestamp":1488014299000},"page":"711-718","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)\/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens"],"prefix":"10.1007","volume":"96","author":[{"given":"Na","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Rong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Zheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi-Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,25]]},"reference":[{"key":"2948_CR1","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s00277-014-2130-0","volume":"93","author":"M Breccia","year":"2014","unstructured":"Breccia M, De Propris MS, Stefanizzi et al (2014) Negative prognostic value of CD34 antigen also in expressed on a small population of acute promyelocytic leukemia cells. Ann Hematol 93:1819\u20131823","journal-title":"Ann Hematol"},{"key":"2948_CR2","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2010-04-277434","volume":"117","author":"P Montesinos","year":"2011","unstructured":"Montesinos P, Rayon C, Vellenga E et al (2011) Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 117:1799\u20131805","journal-title":"Blood"},{"key":"2948_CR3","first-page":"421906","volume":"2014","author":"F Xu","year":"2014","unstructured":"Xu F, Yin CX, Wang CL et al (2014) Immunophenotypes and immune markers associated with acute promyelocytic leukemia prognosis. Dis Mark 2014:421906","journal-title":"Dis Mark"},{"key":"2948_CR4","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00277-014-2142-9","volume":"93","author":"AR Lucena-Araujo","year":"2014","unstructured":"Lucena-Araujo AR, Kim HT, Jacomo RH et al (2014) Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol 93:2001\u20132010","journal-title":"Ann Hematol"},{"key":"2948_CR5","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.ajpath.2013.01.017","volume":"182","author":"W Jia","year":"2013","unstructured":"Jia W, Kidoya H, Yamakawa D et al (2013) Galectin-3 accelerates M2 macrophage infiltration and angiogenesis in tumors. Am J Pathol 182:1821\u20131831","journal-title":"Am J Pathol"},{"key":"2948_CR6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12967-014-0273-3","volume":"12","author":"SS Jiang","year":"2014","unstructured":"Jiang SS, Weng DS, Wang QJ et al (2014) Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med 12:273","journal-title":"J Transl Med"},{"key":"2948_CR7","doi-asserted-by":"crossref","first-page":"e0134458","DOI":"10.1371\/journal.pone.0134458","volume":"10","author":"JT Oliveira de","year":"2015","unstructured":"de Oliveira JT, Ribeiro C, Barros R et al (2015) Hypoxia up-regulates galectin-3 in mammary tumor progression and metastasis. PLoS One 10:e0134458","journal-title":"PLoS One"},{"key":"2948_CR8","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1158\/0008-5472.CAN-12-2424","volume":"72","author":"RR Braeuer","year":"2012","unstructured":"Braeuer RR, Zigler M, Kamiya T et al (2012) Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res 72:5757\u20135766","journal-title":"Cancer Res"},{"key":"2948_CR9","doi-asserted-by":"crossref","first-page":"e25103","DOI":"10.1371\/journal.pone.0025103","volume":"6","author":"SJ Kim","year":"2011","unstructured":"Kim SJ, Shin JY, Lee KD et al (2011) Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One 6:e25103","journal-title":"PLoS One"},{"key":"2948_CR10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00595-012-0378-3","volume":"43","author":"S Yamaki","year":"2013","unstructured":"Yamaki S, Fujii T, Yajima R et al (2013) Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Surg Today 43:901\u2013905","journal-title":"Surg Today"},{"key":"2948_CR11","first-page":"801","volume":"42","author":"ZW Li","year":"2013","unstructured":"Li ZW, Wang Y, Xue WC et al (2013) Expression and prognostic significance of galectin-1 and galectin-3 in benign nevi and melanomas. Zhonghua Bing Li Xue Za Zhi 42:801\u2013805","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"2948_CR12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10238-014-0299-0","volume":"15","author":"MF Leal","year":"2015","unstructured":"Leal MF, Calcagno DQ, Chung J et al (2015) Deregulated expression of annexin-A2 and galectin-3 is associated with metastasis in gastric cancer patients. Clin Exp Med 15:415\u2013420","journal-title":"Clin Exp Med"},{"key":"2948_CR13","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0002-9440(10)64975-9","volume":"156","author":"DK Hsu","year":"2000","unstructured":"Hsu DK, Yang DY, Pan Z et al (2000) Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 156:1073\u20131083","journal-title":"Am J Pathol"},{"key":"2948_CR14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cyto.2014.06.008","volume":"69","author":"R Zhang","year":"2014","unstructured":"Zhang R, Sun T, Song L, Zuo D, Xiao W (2014) Increased levels of serum galectin-3 in patients with primary Sj\u00f6gren's syndrome: associated with interstitial lung disease. Cytokine 69:289\u2013293","journal-title":"Cytokine"},{"key":"2948_CR15","doi-asserted-by":"crossref","first-page":"17468","DOI":"10.1073\/pnas.1111138108","volume":"108","author":"M Yamamoto-Sugitani","year":"2011","unstructured":"Yamamoto-Sugitani M, Kuroda J, Ashihara E et al (2011) Galectin-3 (gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci U S A 108:17468\u201317473","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2948_CR16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0002-9440(10)63177-X","volume":"164","author":"KK Hoyer","year":"2004","unstructured":"Hoyer KK, Pang M, Gui D et al (2004) An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol 164:893\u2013902","journal-title":"Am J Pathol"},{"key":"2948_CR17","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1182\/blood-2012-06-438234","volume":"120","author":"MC Clark","year":"2012","unstructured":"Clark MC et al (2012) Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 120:4635\u20134644. doi: 10.1182\/blood-2012-06-438234","journal-title":"Blood"},{"key":"2948_CR18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000193223","volume":"120","author":"MC Clark","year":"2008","unstructured":"Clark MC, Pang M, Hsu DK et al (2008) Increased serum 90\u00a0K and galectin-3 expression are associated with advanced stage and a worse prognosis indiffuse large B-cell lymphomas. Acta Haematol 120:211\u2013216","journal-title":"Acta Haematol"},{"key":"2948_CR19","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1182\/blood-2012-07-443762","volume":"121","author":"CL Cheng","year":"2013","unstructured":"Cheng CL, Hou HA, Lee MC et al (2013) Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood 121:3172\u20133180","journal-title":"Blood"},{"key":"2948_CR20","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","volume":"13","author":"JJM Dongen van","year":"1999","unstructured":"van Dongen JJM, Macintyre EA, Gabert JA et al (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 13:1901\u20131928","journal-title":"Leukemia"},{"key":"2948_CR21","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VHJ et al (2003) Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe against cancer program. Leukemia 17:2318\u20132357","journal-title":"Leukemia"},{"key":"2948_CR22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3109\/07357907.2010.494319","volume":"28","author":"H Asgarian-Omran","year":"2010","unstructured":"Asgarian-Omran H, Forghani P, Hojjat-Farsangi M, Roohi A, Sharifian RA, Razavi SM et al (2010) Expression profile of galectin-1 and galectin-3 molecules in different subtypes of chronic lymphocytic leukemia. Cancer Investig 28:717\u2013725","journal-title":"Cancer Investig"},{"key":"2948_CR23","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2141.2007.06929.x","volume":"140","author":"N D'Haene","year":"2008","unstructured":"D'Haene N, Catteau X, Maris C, Martin B, Salmon I, Decaestecker C (2008) Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primarycentral nervous system lymphomas. Br J Haematol 140:402\u2013410","journal-title":"Br J Haematol"},{"key":"2948_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-014-0099-8","volume":"8","author":"K Hu","year":"2015","unstructured":"Hu K, Gu Y, Lou L et al (2015) Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt\/\u03b2-catenin signaling pathway. J Hematol Oncol 8:1","journal-title":"J Hematol Oncol"},{"key":"2948_CR25","first-page":"1247","volume":"96","author":"MA Sanz","year":"2000","unstructured":"Sanz MA, Lo Coco F, Mart\u00edn G et al (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247\u20131253","journal-title":"Blood"},{"key":"2948_CR26","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2011.78","volume":"25","author":"S Lehmann","year":"2011","unstructured":"Lehmann S, Ravn A, Carlsson L et al (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish adult acute leukemia registry. Leukemia 25:1128\u20131134","journal-title":"Leukemia"},{"key":"2948_CR27","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1182\/blood-2010-08-302950","volume":"117","author":"G Avvisati","year":"2011","unstructured":"Avvisati G, Lo-Coco F, Paoloni FP et al (2011) AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 117:4716\u20134725","journal-title":"Blood"},{"key":"2948_CR28","doi-asserted-by":"crossref","first-page":"e0121912","DOI":"10.1371\/journal.pone.0121912","volume":"10","author":"E Chendamarai","year":"2015","unstructured":"Chendamarai E, Ganesan S, Alex AA et al (2015) Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. PLoS One 10:e0121912","journal-title":"PLoS One"},{"key":"2948_CR29","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2012-02-410746","volume":"120","author":"HJ Iland","year":"2012","unstructured":"Iland HJ, Bradstock K, Supple SG et al (2012) All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 120:1570\u20131580","journal-title":"Blood"},{"key":"2948_CR30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrc2943","volume":"10","author":"H Th\u00e9 de","year":"2010","unstructured":"de Th\u00e9 H, Chen Z (2010) Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 10:775\u2013783","journal-title":"Nat Rev Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2948-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-2948-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2948-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T23:26:29Z","timestamp":1568849189000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-2948-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,25]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2948"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-2948-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2017,2,25]]}}}